How we do?

AI-based approach

MAbSilico’s technology is based on 20 years of academic research performed by highly competent scientists. Each methods are calibrated using parameters set up from proprietary databases during the R&D stage, and they are all validated with state-of-the-art experimental assays. Thanks to this combined approaches (computational and biology), MAbSilico can show that the predictive data always converge towards the biological truth.

Fast & optimized process

The ML-learning process is made once and for all during the R&D stage. Consequently, computation is generated very fast, within minutes. Using our SaaS MAbFactory, the customers control the process, from their sequences uploading to the export of the final data. MAbSilico’s pipeline allows selecting and optimizing leads within a few days, hence reducing drastically the number of molecules to be tested experimentally before the preclinical trials.

Dedicated support

AI for antibody discovery is new and disruptive. That’s why our handbook provides complete description of the different methods, their output and experimental protocols for experimental validation.
MAbSilico provides experimental validation as well, and we are customer centric with dedicated professional services to help you take the best of the AI-based solutions for your drug discovery program.

On demand solutions

We cover the pre-clinical antibody development pipeline, but some customers might need only a limited number of specific items or have specific needs. Please, inform us of your problematic, we can implement an on-demand package for your specific program, and if no method seems to reply to your scientific concern, we may be able to adapt or design a method to solve your problem.